The Times of India, 15 September 2012
The Crest Edition
Curiously enough, the antagonists in the pharma patents battle seem to be working towards a similar goal – a better deal for patients. But one is fighting for affordability and access, the other is arguing for innovation and discovery.
The conflict is this: innovators want to cover their costs by pricing their medicines high, while generic medicine manufacturers want to roll out cheaper copies of these molecules and provide cheaper medicines to those who cannot afford it.
Click here to read the full article